Hsbc Holdings PLC Takes $879,000 Position in Integra LifeSciences Holdings Corporation $IART

Hsbc Holdings PLC purchased a new stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 70,305 shares of the life sciences company’s stock, valued at approximately $879,000.

A number of other hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in Integra LifeSciences during the 4th quarter valued at $4,722,000. Tejara Capital Ltd raised its stake in shares of Integra LifeSciences by 42.6% in the fourth quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock worth $2,134,000 after purchasing an additional 51,300 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Integra LifeSciences by 15.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 526,302 shares of the life sciences company’s stock worth $6,537,000 after purchasing an additional 71,950 shares during the last quarter. Systematic Financial Management LP lifted its holdings in shares of Integra LifeSciences by 4.5% during the fourth quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock valued at $13,769,000 after purchasing an additional 48,094 shares in the last quarter. Finally, UBS Group AG lifted its holdings in shares of Integra LifeSciences by 211.7% during the fourth quarter. UBS Group AG now owns 408,969 shares of the life sciences company’s stock valued at $5,079,000 after purchasing an additional 277,745 shares in the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Wall Street Zen raised Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research report on Thursday, June 18th. Truist Financial lowered their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th. Citigroup reaffirmed a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Finally, Wells Fargo & Company lifted their price target on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $17.17.

Integra LifeSciences Price Performance

NASDAQ IART opened at $18.40 on Wednesday. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -2.85, a PEG ratio of 1.29 and a beta of 1.22. Integra LifeSciences Holdings Corporation has a 1-year low of $8.70 and a 1-year high of $18.92. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. The business’s fifty day moving average price is $16.59 and its 200-day moving average price is $12.94.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.41 by $0.13. The company had revenue of $391.92 million during the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.Integra LifeSciences’s revenue was up 2.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.